.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX17_SipuleucelT.SipuleucelT .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX17_SipuleucelT.SipuleucelT| name: | SipuleucelT |
| ATC code: | L03AX17 | route: | intravenous |
| n-compartments | 0 |
Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is prepared from a patient’s own peripheral blood mononuclear cells and activated ex vivo with a recombinant fusion protein (PAP-GM-CSF). Sipuleucel-T is approved and used clinically in certain countries including the United States.
No classical pharmacokinetic parameters are reported for sipuleucel-T as it is a cellular therapy involving personalized, autologous immune cells and not a traditional small molecule or biologic drug. Pharmacokinetics in the conventional sense (e.g., absorption, distribution, metabolism, elimination) are not applicable to this therapy based on published literature and regulatory documents.